PD-1/PD-L1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展  

Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for Non-small Cell Lung Cancer

作　　者：林城[1] 陈雄[1] 刘静南[1] 黄于芳 欧阳学农[1] 

机构地区：[1]南京军区福州总医院肿瘤科,福州350025

出　　处：《中国肺癌杂志》2014年第10期734-740,共7页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金项目(No.81274002)资助~~

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)是肿瘤相关性死亡率第一的恶性肿瘤。虽然近年来靶向治疗进展迅速,但很多基因未突变的患者不能从中受益。目前免疫治疗已成为肿瘤治疗的新方向,它能通过刺激机体免疫系统提高抗肿瘤免疫效应。研究显示免疫检查点分子:程序性死亡分子1(programmed death 1,PD-1)、程序性死亡分子1配体(PD-1 ligand,PD-L1),与肿瘤发生、发展密切相关,在NSCLC中有重要的临床意义。PD-1/PD-L1信号通路的激活有助于肿瘤免疫逃逸,而阻断该通路可以增强机体内源性抗肿瘤免疫效应。目前越来越多的临床试验显示免疫检查点阻滞剂抗PD-1、抗PD-L1抗体在治疗NSCLC中的良好疗效性和安全性。本综述旨在回顾及总结近年来PD-1/PD-L1信号通路及其阻滞剂在NSCLC中的研究进展。Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get beneift from them. Immunotherapy, through stimulating the body＆#39;s immune system to improve the antitumor immunity effect, has been a new therapeutic method for non-small cell lung cancer （NSCLC）. Study had been reported that immune checkpoint molecules, including programmed death-1 （PD-1）/PD-ligand （L） 1 axis, are closedly related with cancer generation and development, and play a key role on clinical signiifcance of NSCLC. Activation of PD-1/PD-L1 pathway contributes to tumor immune escape, and block PD-1/PD-L1 pathway can enhance endogenous antimuor immunity. Currently increasing clinical trials suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies turned out to be beneifcial and safe in NSCLC. Here, we provide a review on the progress of PD-1/PD-L1 pathway and immune checkpoint inhibitors in NSCLC.

关 键 词：肺肿瘤 程序性死亡分子1 程序性死亡分子1配体 免疫治疗 调定点阻滞剂 免疫逃逸 

分 类 号：R734.2[医药卫生—肿瘤]